Additionally, genetic studies show that alterations in the EGFR pathway are rare (21%) and predominant in the HPV− population (15% HPV− vs. 6% HPV+), which suggest that these inhibitors are less likely to work in HPV+ HNSCC patients [20,32,35,83,84]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.